DAX24.185 -0,1%Est505.663 -0,1%MSCI World4.343 -0,1%Top 10 Crypto15,26 +0,4%Nas22.942 +0,9%Bitcoin95.907 +1,2%Euro1,1610 -0,1%Öl65,98 ±0,0%Gold4.070 -1,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Beyond Meat A2N7XQ TKMS thyssenkrupp Marine Systems TKMS00 Rheinmetall 703000 NVIDIA 918422 D-Wave Quantum A3DSV9 SAP 716460 RENK RENK73 Tesla A1CX3T DroneShield A2DMAA Infineon 623100 Deutsche Telekom 555750 Siemens Energy ENER6Y Plug Power A1JA81 Volkswagen (VW) vz. 766403 Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hoffnung auf Entspannung im Handelsstreit: DAX unentschlossen -- Asiens Börsen fest -- Intel: Starke Zahlen -- HENSOLDT: Höhere Ziele -- DroneShield, SuperMicro, TKMS, Beyond Meat, Dow im Fokus
Top News
Vor US-Inflationsdaten: DAX im Freitagshandel erneut unentschlossen Vor US-Inflationsdaten: DAX im Freitagshandel erneut unentschlossen
Comfort Systems: Vom Infrastruktur-Dienstleister zum KI-Profiteur Comfort Systems: Vom Infrastruktur-Dienstleister zum KI-Profiteur
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Akebia Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,51 EUR -0,05 EUR -2,11 %
FSE
2,98 USD -0,01 USD -0,17 %
BTT
Akebia Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.682,79 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XF0S

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00972D1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAKBA

Akebia Therapeutics Aktien News

DatumMeistgelesen
PR NewswireAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
PR NewswireAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Secures $55 Million Term Loan Financing
PR NewswireAkebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Piper Sandler Healthcare Conference
PR NewswireAkebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
PR NewswireAkebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
PR NewswireAkebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
PR NewswireAkebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
PR NewswireAkebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023
PR NewswireAkebia Therapeutics Provides Update on Form 10-Q Filing
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
PR NewswireAkebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
PR NewswireAkebia Announces Swissmedic Approval of Vafseo® (vadadustat)
PR NewswireAkebia Therapeutics Announces New Chief Financial Officer
PR NewswireAkebia Therapeutics to Present at Jefferies Healthcare Conference
PR NewswireFDA Provides Akebia Therapeutics a Path Forward for Vadadustat

Akebia Therapeutics News

Akebia Therapeutics News: auf dieser Seite finden Sie alle Akebia Therapeutics News und Nachrichten zur Akebia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akebia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Akebia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.